Literature DB >> 24964977

The role of surgeons in building a personalized medicine program.

Genevieve M Boland1, Funda Meric-Bernstam.   

Abstract

Changes in technology, with decreases in the cost of molecular profiling, has expanded the interest in creating institution-wide personalized medicine platforms to allow selective assessment of a given patient's tumor in real time, with the ability to utilize that information for patient-care decisions. In order for this approach to function adequately, a multidisciplinary team must be created in an environment with dedicated support at an institutional level.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  genomics; next-generation sequencing; personalized medicine; precision medicine

Mesh：

Year:  2014        PMID： 24964977      PMCID： PMC4285684          DOI： 10.1002/jso.23684

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  29 in total

1.  TGF-β1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis.

Authors:  Fernanda T Borges; Sonia A Melo; Berna C Özdemir; Noritoshi Kato; Ignacio Revuelta; Caroline A Miller; Vincent H Gattone; Valerie S LeBleu; Raghu Kalluri
Journal:  J Am Soc Nephrol       Date:  2012-12-28       Impact factor: 10.121

Review 2.  Cell-free nucleic acids as biomarkers in cancer patients.

Authors:  Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2011-05-12       Impact factor: 60.716

Review 3.  Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.

Authors:  B Glimelius; M Lahn
Journal:  Ann Oncol       Date:  2011-01-13       Impact factor: 32.976

Review 4.  Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology.

Authors:  Maureen Cronin; Jeffrey S Ross
Journal:  Biomark Med       Date:  2011-06       Impact factor: 2.851

Review 5.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

6.  Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.

Authors:  Héctor Peinado; Maša Alečković; Simon Lavotshkin; Irina Matei; Bruno Costa-Silva; Gema Moreno-Bueno; Marta Hergueta-Redondo; Caitlin Williams; Guillermo García-Santos; Cyrus Ghajar; Ayuko Nitadori-Hoshino; Caitlin Hoffman; Karen Badal; Benjamin A Garcia; Margaret K Callahan; Jianda Yuan; Vilma R Martins; Johan Skog; Rosandra N Kaplan; Mary S Brady; Jedd D Wolchok; Paul B Chapman; Yibin Kang; Jacqueline Bromberg; David Lyden
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

7.  Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.

Authors:  Jian Wu; Hanno Matthaei; Anirban Maitra; Marco Dal Molin; Laura D Wood; James R Eshleman; Michael Goggins; Marcia I Canto; Richard D Schulick; Barish H Edil; Christopher L Wolfgang; Alison P Klein; Luis A Diaz; Peter J Allen; C Max Schmidt; Kenneth W Kinzler; Nickolas Papadopoulos; Ralph H Hruban; Bert Vogelstein
Journal:  Sci Transl Med       Date:  2011-07-20       Impact factor: 17.956

8.  Circulating tumour cells in non-metastatic breast cancer: a prospective study.

Authors:  Anthony Lucci; Carolyn S Hall; Ashutosh K Lodhi; Anirban Bhattacharyya; Amber E Anderson; Lianchun Xiao; Isabelle Bedrosian; Henry M Kuerer; Savitri Krishnamurthy
Journal:  Lancet Oncol       Date:  2012-06-06       Impact factor: 41.316

Review 9.  Building a personalized medicine infrastructure at a major cancer center.

Authors:  Funda Meric-Bernstam; Carol Farhangfar; John Mendelsohn; Gordon B Mills
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

10.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

Authors:  S Paik; R Hazan; E R Fisher; R E Sass; B Fisher; C Redmond; J Schlessinger; M E Lippman; C R King
Journal:  J Clin Oncol       Date:  1990-01       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.